Review | Open Access
Roger B Cohen, Karen A Dittrich, "Anti-TNF Therapy and Malignancy – A Critical Review", Canadian Journal of Gastroenterology and Hepatology, vol. 15, Article ID 403102, 9 pages, 2001. https://doi.org/10.1155/2001/403102
Anti-TNF Therapy and Malignancy – A Critical Review
The roles of tumour necrosis factor (TNF) and anti-TNF therapy in malignancy are reviewed, including an overview of baseline risk factors for malignancy in inflammatory diseases and the incidences of malignancies observed in clinical trials of an anti-TNF-a therapy, infliximab. The preclinical data and early clinical experience presented for infliximab do not provide evidence for a causal relationship between TNF-a antagonism and the development of lymphoid or nonlymphoid cancers.
Copyright © 2001 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.